Voyager Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on events occurring on June 9, 2026, specifically the 2026 Annual Meeting of Stockholders for Voyager Therapeutics, Inc. (VYGR), a biopharmaceutical company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
- Capital Structure Amendment: Stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation. The total authorized shares of capital stock increased from 125,000,000 to 245,000,000. Specifically, authorized common stock increased from 120,000,000 to 240,000,000 shares.
- Board of Directors: Stockholders elected James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D., as Class II directors for terms ending at the 2029 Annual Meeting.
- Executive Compensation: Stockholders approved a non-binding advisory proposal regarding the compensation of named executive officers.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary on future financial guidance, operational outlook, or specific risk factors. The primary focus is the successful execution of shareholder votes and the legal amendment of the company's charter.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment with the Delaware Secretary of State (filed June 9, 2026).
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for any additional provisions regarding the new authorized shares.
- Confirm the voting results for the Class II directors, noting the significant number of broker non-votes (13,057,844) which did not affect the election outcome.
- Check subsequent filings for any immediate issuance of shares from the newly authorized pool.